Adherex Technologies (FENC)
(Real Time Quote from BATS)
$9.18 USD
-0.03 (-0.33%)
Updated Apr 29, 2024 12:42 PM ET
3-Hold of 5 3
D Value D Growth D Momentum F VGM
Price, Consensus and EPS Surprise
FENC 9.18 -0.03(-0.33%)
Will FENC be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for FENC based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for FENC
Adherex Technologies Inc. (FENC) Reports Q4 Loss, Tops Revenue Estimates
Fennec (FENC) Signs Licensing Deal With Norgine, Stock Up
FENC: What are Zacks experts saying now?
Zacks Private Portfolio Services
Adherex Technologies Inc. (FENC) is on the Move, Here's Why the Trend Could be Sustainable
Wall Street Analysts See a 64.61% Upside in Adherex Technologies Inc. (FENC): Can the Stock Really Move This High?
Recent Price Trend in Adherex Technologies Inc. (FENC) is Your Friend, Here's Why
Other News for FENC
FENC Makes Notable Cross Below Critical Moving Average
Insider Sell: CEO Rosty Raykov Sells 88,583 Shares of Fennec Pharmaceuticals Inc (FENC)
Buy Rating Reaffirmed for Fennec Pharmaceuticals Following Strategic European Licensing Deal and Strong Financial Outlook
Fennec price target raised by $1 at H.C. Wainwright, here's why
Fennec Pharmaceuticals Inc CEO Rosty Raykov Sells 40,584 Shares